Novo Nordisk's Multi-Pronged Defense: A Pill Approval, a Buyback, and a Cloud Alliance

Novo Nordisk counters Eli Lilly's lead with oral Wegovy EU approval, AWS partnership, and buybacks, but investors remain cautious.

The narrative around Novo Nordisk has increasingly been framed as a two-horse race, with Eli Lilly cast as the frontrunner in the obesity-treatment gold rush. But the Danish pharmaceutical giant is pushing back on that storyline, arguing that the market for weight-loss drugs is big enough for more than one winner.

Speaking on August 13, CEO Mike Doustdar rejected the notion that Eli Lilly has permanently pulled ahead in the lucrative GLP-1 arena. His counter-argument rests on a combination of new drug delivery formats and a broader product portfolio, with the oral version of Wegovy serving as the company's flagship response.

That pill is no longer just a pipeline promise. The European Commission granted marketing authorization for oral Wegovy on July 15, following a positive recommendation from the European Medicines Agency. The approval hands Novo Nordisk a licensed oral GLP-1 therapy in Europe, putting it in direct competition with Lilly's ambitions in the same space.

A Narrowing Window of Advantage

The regulatory head start, however, is already shrinking. Eli Lilly secured its first European approval for its own oral weight-loss pill, Foundayo, in the UK on August 10 — a move that underscores just how quickly the competitive landscape is shifting. Investors betting on a sustained Novo advantage in the oral segment may need to recalibrate their expectations.

Doustdar's response has been to lean into growth through acquisition. The company intends to accelerate its research pace and is actively evaluating smaller, bolt-on deals to fortify its pipeline, according to Reuters.

That strategy follows a raised full-year outlook issued alongside the half-year results roughly two weeks ago. The market's reaction was muted at best — the shares gained just 2.8 percent in the aftermath, a sign that operational progress alone is no longer moving the needle for investors.

Capital Returns and Cloud Computing

While the competitive battle plays out, Novo Nordisk has been quietly returning capital to shareholders. Between August 10 and 14, the company repurchased one million B-shares for 302.6 million Danish kroner, bringing its total treasury holdings to 42,924,876 B-shares — equivalent to one percent of share capital. The buyback is part of an ongoing program that signals management's confidence in the company's valuation.

The same week brought a different kind of strategic move. On August 17, Novo Nordisk announced a partnership with Amazon Web Services, naming AWS its preferred cloud provider and establishing a joint co-innovation center in London. The collaboration is aimed at deploying agentic AI and cloud technologies in drug discovery — a signal that the company is investing in future capabilities even as its growth momentum has cooled.

Shareholders have a few dates to circle. Those on the register as of August 17 will receive a dividend of 0.5786 US dollars per share on August 25. A capital markets day follows on September 21, where management is expected to lay out strategy, operational targets, and financial metrics. First-nine-month results for 2026 are slated for November 4.

Legal Wins and a Production Setback

On the litigation front, Novo Nordisk has notched two victories that bolster its patent defenses in an environment where compounded knockoffs are pressuring pricing. A US federal court in Texas dismissed an antitrust case brought by Strive Specialties, which had accused Novo Nordisk and Eli Lilly of illegally blocking customized versions of their obesity drugs. The court found the plaintiff failed to demonstrate that compounded and branded GLP-1 products were interchangeable in the manner alleged.

In the Netherlands, the company secured a preliminary injunction against Ceban Ziekenhuisfarmacie over a semaglutide patent violation involving a compounded nasal spray. The court ordered the pharmacy to halt the infringing activities and disclose supply chain information.

Not everything has gone Novo's way. The company's manufacturing footprint suffered a blow when partner Scholar Rock removed a Novo-operated facility in Indiana from a US regulatory filing, following an inspection in April that uncovered significant compliance deficiencies. The plant came from the Catalent acquisition completed in 2024.

The Stock's Stubborn Stalemate

For all the strategic activity, the share price tells a more cautious story. The stock closed at 39.52 euros on Tuesday, up 1.7 percent on the day, but that bounce does little to offset a broader slide. The shares remain roughly 28 percent below their 52-week high of 54.86 euros, reached in late January. On a monthly basis, the stock is down 9.1 percent, and it has lost 10 percent since the start of the year.

Technical indicators paint a picture of a market that is neither euphoric nor panicked. The RSI sits at 42.2, suggesting neutral momentum, while annualized volatility of 40 percent points to persistently jittery trading conditions.

The central question for investors remains whether the oral Wegovy approval, the acquisition appetite, and the defensive legal wins will be enough to close the gap with Eli Lilly — or whether the market's skepticism is telling them something the company's press releases are not. The upcoming capital markets day may offer the clearest signal yet.